Cost-effectiveness antitrypsin replacement therapy treatment congenital chronic obstructive pulmonary disease BACKGROUND Alpha AAT replacement therapy expensive intervention patient progression chronic obstructive pulmonary disease COPD AAT-deficient patients FDA-approved therapy efficacy unknown costs benefits AAT replacement therapy patients congenital COPD METHODS Epidemiological disease cost data sources discrete-time model disease stage probability transition present-value expected cost disease treatment range possible therapy efficacy parameter values RESULTS efficacy percent cost life year AAT replacement therapy US dollars patient age sex smoking status percent efficacy cost life year range controlled efficacy study true efficacy percent CONCLUSIONS efficacy percent therapy cost-effectiveness comparable medical interventions economic assessment methodology therapeutic innovation value additional clinical research 